sna-120
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2017 (NCT03322137)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nerve growth factor receptor Trk-AANTAGONIST
NTRK1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sna-120
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03448081 | Phase 2 | Feb 12, 2018 | Sienna Biopharmaceuticals |
| NCT03322137 | Phase 2 | Oct 10, 2017 | Sienna Biopharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sienna Biopharmaceuticals | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1